Chardan Capital analyst Keay Nakae reiterated a Buy rating on Axcella Health (AXLA – Research Report) today and set a price target of $10.00. The company’s shares closed last Thursday at $3.60, close to its 52-week low of $3.03.
According to TipRanks.com, Nakae is a 5-star analyst with an average return of 21.7% and a 45.3% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Adverum Biotechnologies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Axcella Health with a $11.80 average price target, a 224.2% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $14.00 price target.
Based on Axcella Health’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $15.19 million. In comparison, last year the company had a GAAP net loss of $15.01 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.